Serum-free cell culture market seen reaching $7.76B by 2030

The Business Research Company says the serum-free cell culture market will grow from $4.11 billion in 2025 to $4.66 billion in 2026, then reach $7.76 billion by 2030. The report points to rising cell and gene therapy demand, biopharmaceutical manufacturing and vaccine development as the main growth drivers.

Why it matters: - Serum-free cell culture is a core input for biopharmaceutical production, vaccine manufacturing, monoclonal antibodies and cell and gene therapies. - Growth in this market tracks broader expansion in advanced therapies and biologics manufacturing. - The market’s forecast points to continued demand for standardized, reproducible and animal component-free systems.

What happened: - The Business Research Company released its latest Serum-Free Cell Culture Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the market will rise from $4.11 billion in 2025 to $4.66 billion in 2026. - The report projects the market will reach $7.76 billion by 2030. - The company links the near-term expansion to biopharmaceutical manufacturing, vaccine development, monoclonal antibody production, regenerative medicine research and life sciences investment.

The details: - Serum-free cell culture media are formulated without animal-derived serum. - The media are designed to support growth, maintenance and production of cells under controlled in vitro conditions. - The formulations include amino acids, vitamins, minerals, recombinant growth factors, hormones and other nutrients. - The report identifies rising commercialization of cell and gene therapies, larger biologics capacity and more bioprocess development spending as key long-term drivers. - The report highlights a shift toward chemically defined media, animal component-free systems, xeno-free media, high-yield culture techniques and standardized workflows. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics. - The report is available as a full market report, and a free sample is also offered.

Between the lines: - The market outlook reflects pressure on drug developers and manufacturers to scale production while keeping workflows consistent and contamination risk low. - The ASGCT reported 76 new gene therapy clinical trials launched globally in July 2024, up 25% from the prior quarter, which underscores the pace of activity in the sector. - The strongest growth signals cluster around therapies and manufacturing methods that depend on controlled, serum-free systems.

What's next: - Demand should continue to rise as cell and gene therapies move further into commercialization. - Adoption is likely to increase for advanced serum-free formulations that support scalable biologics production. - Regional momentum is expected to stay strongest in Asia-Pacific as healthcare capacity and advanced culture technology adoption expand.

The bottom line: - Serum-free cell culture is moving from a specialized tool to a more central platform for next-generation biologics and therapies.